Alnylam reports positive topline results from illuminate-a phase 3 study of lumasiran for the treatment of primary hyperoxaluria type 1

Alnylam reports positive topline results from illuminate-a phase 3 study of lumasiran for treatment of primary hyperoxaluria type 1.alnylam pharma - lumasiran met primary and all tested secondary endpoints, with significant reduction in urinary oxalate levels relative to placebo.alnylam pharmaceuticals - intends to file nda and marketing authorisation application for lumasiran in early 2020.alnylam pharmaceuticals - lumasiran also demonstrated encouraging safety and tolerability profile in illuminate-a phase 3 study.
ALNY Ratings Summary
ALNY Quant Ranking